Small colony variants of Staphylococcus aureus--review.
Bacterial variants of Staphylococcus aureus called small colony variants (SCVs) originate by mutations in metabolic genes, resulting in emergence of auxotrophic bacterial subpopulations. These variants are not particularly virulent but are able to persist viable inside host cells. SCVs show their characteristic auxotrophic growth deficiency and depressed α-cytotoxin activity. Environmental pressure such as antibiotics, select for isogenic SCV cells that are frequently found coexisting with their parent wild-type strains in a mixed bacterial culture. SCV strains often grow on blood agar as non-pigmented or pinpoint pigmented colonies and their key biochemical tests are often non-reactive. Their altered metabolism or auxotrophism can result in long generation time and thus SCV phenotype, more often than not SCV can be overgrown by their wild-type counterparts and other competitive respiratory flora. This could affect laboratory detection. Thus, molecular methods, such as 16S rRNA partial sequencing or amplification of species-specific DNA targets (e.g. coagulase, nuclease) directly from clinical material or isolated bacterial colonies, become the method of choice. Patients at risk of infection by S. aureus SCVs include cystic fibrosis patients (CF), patients with skin and foreign-body related infections and osteomyelitis, as they suffer from chronic staphylococcal infections and are subject to long-term antibiotic therapy. Molecular evidence of SCV development has not been found except for some random mutations of the thymidylate synthase gene (thyA) described in SCV S. aureus strains of CF patients. These variants are able to bypass the antibiotic effect of folic acid antagonists such as sulfonamides and trimethoprim. Resistance to gentamicin and aminoglycosides in the hemin or menadione auxotrophic SCVs was hypothesized as being due to decreased influx of the drugs into cells as a result of decreased ATP production and decreased electrochemical gradient on cell membranes.
Department of Medical Microbiology, 2nd Medical Faculty, Charles University in Prague, Prague 5-Motol, Czech Republic. oto.melter@lfmotol.cuni.cz
O
O
Melter
B
B
Radojevič
D014644:Genetic Variation; D006801:Humans; D053858:Metabolic Networks and Pathways / Q000235:genetics*; D009154:Mutation; D013203:Staphylococcal Infections / Q000382:microbiology; D013211:Staphylococcus aureus / Q000235:genetics / Q000254:growth & development* / Q000378:metabolism* / Q000472:pathogenicity; D014774:Virulence; D037521:Virulence Factors / Q000378:metabolism
D037521:Virulence Factors
J Clin Microbiol. 1991 Mar;29(3):426-30
2037659
Clin Infect Dis. 1999 Nov;29(5):1128-32
10524952
Trends Microbiol. 2009 Feb;17(2):54-8
19162480
J Infect Dis. 1994 Oct;170(4):1033-7
7930701
J Bacteriol. 2006 Jan;188(2):687-93
16385058
J Clin Microbiol. 2008 Nov;46(11):3829-32
18832128
J Bacteriol. 1997 Aug;179(15):4706-12
9244256
J Clin Microbiol. 2000 Mar;38(3):1008-15
10698988
Int J Artif Organs. 2007 Sep;30(9):778-85
17918122
J Mol Med (Berl). 2007 May;85(5):461-9
17216207
J Clin Microbiol. 2003 Apr;41(4):1434-9
12682126
Trends Microbiol. 2009 Feb;17(2):59-65
19208480
J Infect Dis. 2010 Oct 1;202(7):1031-40
20715929
J Clin Microbiol. 2004 Nov;42(11):4988-95
15528685
Antonie Van Leeuwenhoek. 1973;39(1):33-40
4540258
Emerg Infect Dis. 2005 Aug;11(8):1283-6
16102320
J Clin Pathol. 1955 Nov;8(4):284-7
13271575
J Clin Pathol. 1955 Nov;8(4):288-91
13271576
J Bacteriol. 1942 Jul;44(1):127-36
16560541
J Bacteriol. 2007 Jan;189(1):119-30
17071749
J Infect Dis. 1998 Apr;177(4):1023-9
9534977
J Clin Pathol. 1978 Aug;31(8):724-9
99457
J Clin Microbiol. 2004 Mar;42(3):1277-9
15004093
J Clin Invest. 1954 Dec;33(12):1611-22
13211817
J Bacteriol. 1958 Aug;76(2):136-41
13563407
J Clin Microbiol. 1978 Dec;8(6):629-34
370140
Infect Immun. 1994 May;62(5):1843-7
8168947
J Infect Dis. 1996 Mar;173(3):739-42
8627043
J Clin Pathol. 1952 Nov;5(4):354-5
13011225
J Infect Dis. 1987 Mar;155(3):581-5
3643249
J Clin Microbiol. 2006 Oct;44(10):3804-7
17021116
Int J Med Microbiol. 2010 Feb;300(2-3):170-5
19781990
J Clin Microbiol. 2007 Jan;45(1):168-72
17108072
Microbes Infect. 2001 Jan;3(1):23-35
11226851
Int J Antimicrob Agents. 2008 Jun;31(6):507-10
18180148
Clin Infect Dis. 1999 Sep;29(3):621-5
10530458
FEMS Immunol Med Microbiol. 2002 Feb 18;32(3):191-7
11934563
Microbiol Rev. 1982 Sep;46(3):241-80
6127606
J Bacteriol. 2008 Feb;190(3):834-42
17905979
Clin Microbiol Rev. 2002 Apr;15(2):194-222
11932230
Int J Med Microbiol. 2003 Dec;293(6):427-35
14760974
PLoS Pathog. 2010 Mar 12;6(3):e1000804
20300602
J Bacteriol. 2003 Dec;185(23):6928-37
14617657
J Clin Microbiol. 1976 Oct;4(4):343-8
977733
Clin Infect Dis. 1998 Aug;27 Suppl 1:S68-74
9710673
J Bacteriol. 2006 Nov;188(22):7765-77
16980462
J Clin Microbiol. 2005 Apr;43(4):1956-9
15815031
Nat Rev Microbiol. 2006 Apr;4(4):295-305
16541137
Lancet. 1969 Dec 27;2(7635):1425-6
4188305
J Mol Med (Berl). 2010 Jun;88(6):565-75
20151104
Curr Biol. 2001 Nov 13;11(22):1810-4
11719226
Antimicrob Agents Chemother. 2008 Nov;52(11):4017-22
18779359
J Clin Microbiol. 2003 Jan;41(1):410-3
12517881
Emerg Infect Dis. 1999 May-Jun;5(3):450-3
10341185
J Bacteriol. 1945 Nov;50(5):585-7
16561032
Clin Infect Dis. 1997 Nov;25(5):1250-1
9402396
Science. 2000 May 19;288(5469):1251-4
10818002
Clin Infect Dis. 1999 Oct;29(4):932-4
10589914
J Med Microbiol. 2003 Apr;52(Pt 4):295-301
12676867
Thromb Haemost. 2005 Aug;94(2):266-77
16113815
J Clin Microbiol. 2007 Feb;45(2):529-35
17135443
J Clin Microbiol. 2006 Sep;44(9):3274-8
16954260
Clin Infect Dis. 1995 Jan;20(1):95-102
7727677
Clin Infect Dis. 2001 Jun 1;32(11):1643-7
11340539
J Bacteriol. 2007 Apr;189(7):2936-40
17259321
Yale J Biol Med. 1969 Apr;41(5):394-403
5780692
J Clin Microbiol. 2008 May;46(5):1832-4
18322058
J Med Microbiol. 1969 Aug;2(3):187-97
5404799
J Clin Microbiol. 2003 Sep;41(9):4424-7
12958283